ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 24 Issue : 2
Current Issue Archive Popular Article Ahead of Print

 
Autologous stem cell therapy with surgical myocardial revascularization - The Rostock University experience [Anatol J Cardiol]
Anatol J Cardiol. 2009; 9(6): 457-464

Autologous stem cell therapy with surgical myocardial revascularization - The Rostock University experience

Can Yerebakan1, Murat Uğurlucan1, Alexander Kaminski1, Bernd Westphal1, Andreas Liebold1, Gustav Steinhoff1
Rostock Üniversitesi Tıp Fakültesi, Kalp Cerrahisi Kliniği, Rostock, Germany

Objective: Stem cell therapy has gained great attraction in the treatment of acute and chronic myocardial diseases in recent years. The aim was to evaluate our experience in light of the middle term results of intramyocardial stem cell treatment with concomitant coronary artery bypass surgery (CABG) since 2001. Methods: After encouraging initial results of the Phase I (safety) trial with the first 15 patients, a prospective, controlled Phase II (efficacy) study was begun with 40 patients aiming to determine functional benefit of stem cell treatment using bone marrow derived CD 133+ stem cell therapy with concomitant CABG in comparison to CABG only since 2003. Medium-term results of intervention were evaluated using patient’s clinical findings, Holter monitoring, echocardiography, magnetic resonance imaging, computed tomography and myocardial scintigraphy. Statistical analyses were performed using unpaired t, Mann-Whitney U, ANOVA for repeated measurements and Chi-square tests. Results: Left ventricular ejection fraction (LVEF) has increased significantly at 6th and 18th months follow-up in the first 15 patients who received therapy since 2001 (preoperative: 39.0±8.7%; 6th month: 50.2±8.5% and 18th month: 47.9±6.0%; p=0.012). In the late group of patients, LVEF increased from 37.4±8.4% to 47.1±8.3% (p<0.001) whilst although an increase in LVEF has been observed in the CABG alone group (from 37.9±10.3% to 41.3±9.1%) the increase has not been statistically significant. Mortality occurred in 2 patients [1 patient from the early and 1 patient from the medium term follow-up] due to non-cardiac reasons. Myocardial calcification, lethal ventricular arrhythmia, and tumor formation have not been observed in any of the patients in the long-term follow up. Conclusion: Direct injection of bone marrow derived CD 133+ stem cells into the myocardium with concomitant CABG is safe. However, this treatment modality may only be applied as standard treatment after completion of the long term detailed results of prospective, randomized multicenter trials.

Keywords: Stem cell, myocardial ischemia, heart failure, cardiac surgery


Can Yerebakan, Murat Uğurlucan, Alexander Kaminski, Bernd Westphal, Andreas Liebold, Gustav Steinhoff. Autologous stem cell therapy with surgical myocardial revascularization - The Rostock University experience. Anatol J Cardiol. 2009; 9(6): 457-464


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2019 Turkish Society of Cardiology